Close Menu

NEW YORK (GenomeWeb) – Admera Health today announced it has completed a Series A financing round.

The New Jersey-based molecular diagnostics firm did not disclose the sum raised in the funding round, but said it is planning to use the capital to "expand operations aggressively" and accelerate product development efforts.

The financing round was led by investment firm Prime Value Capital Management (PVCM) and was joined by Sungent Bioventure, a venture capital firm based in Suzhou, China. PVCM's founding partner Chenhui Wen will join Admera's board of directors, Admera said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.